Alms.O
Alumis Inc operates in the Health Care sector, specifically within the Pharmaceuticals industry, though its specific business activity remains unclassified in the available data.
Business. Alumis Inc operates in the Health Care sector, specifically within the Pharmaceuticals industry, though its specific business activity remains unclassified in the available data.
Analyst recommendations
10 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Alumis Inc operates in the Health Care sector, specifically within the Pharmaceuticals industry, though its specific business activity remains unclassified in the available data.
Alumis Inc maintains a conservative capital structure with zero debt, resulting in a debt-to-equity ratio of 0.0. The company holds $89.67 million in cash and equivalents against total liabilities of $110.64 million, providing a current liquidity buffer. However, the balance sheet reflects a market capitalization of $2.38 billion, which implies a price-to-book ratio of 7.9, significantly above typical mature industry norms. The high valuation multiple suggests the market is pricing in future growth or asset value not yet reflected in the tangible book value of $301.30 million.
Profitability metrics are deeply negative, reflecting a pre-revenue or early-stage commercial profile. The company reported a net loss of $243.33 million on revenue of only $24.05 million, resulting in a return on equity of -78.8% and a return on assets of -57.6%. These figures indicate that the company is currently burning cash to fund operations, with operating cash flow at -$369.52 million. The negative EV/EBITDA of -8.72 further underscores the lack of current earnings power.
Segment and geographic revenue breakdowns are not provided in the available data, preventing an analysis of revenue concentration or regional exposure. The absence of this data limits the ability to assess diversification risks or specific market dependencies.
Growth trajectory analysis is constrained by the lack of historical period data. The current revenue figure of $24.05 million stands in stark contrast to the significant operating losses, suggesting that the company is in a phase of heavy investment rather than organic revenue expansion. Without historical trends, it is not possible to determine if revenue is accelerating or decelerating.
Risk assessment indicates low liquidity risk and low dilution risk, with no immediate filing-based flags detected. The primary risk appears to be execution and commercialization, given the substantial cash burn relative to the cash on hand. The low dilution risk suggests that the company has not recently engaged in aggressive equity issuance, preserving existing shareholder value despite the losses.
Recent observations include strong analyst sentiment, with a mean recommendation of 1.50 (Strong Buy) and a mean price target of $40.11, implying significant upside from the current market price of $28.00. The high price target range, with a high of $55.00, suggests that analysts expect a positive catalyst or successful commercialization event in the near term.
- The company is debt-free with a strong cash position of $89.67 million, but faces significant cash burn with operating cash flow of -$369.52 million.
- Valuation is high at a P/B of 7.9 and EV/Revenue of 272.69, indicating the market is pricing in substantial future growth potential.
- Profitability is negative with a net loss of $243.33 million, resulting in negative ROE and ROA.
- Analyst sentiment is strongly positive with a mean recommendation of 1.50 and a mean price target of $40.11.
- Classification confidence is low (0.20), and specific business activities are unclassified, limiting detailed operational analysis.
Bull / Bear case
analysis pipelineIn focus — financials by report
Revenue $1.7M, −90,0% YoY; Operating income +3,1% YoY.
- ▍Revenue $1.7M, −90,0% YoY
- ▍Operating income +3,1% YoY
- ▍Net income +6,0% YoY
- ▍Free cash flow +6,0% YoY
- ▍Net margin -5344.8%
Revenue $1.9M; Operating income +2,2% YoY.
- ▍Revenue $1.9M
- ▍Operating income +2,2% YoY
- ▍Net income +1,9% YoY
- ▍Free cash flow +2,3% YoY
- ▍Net margin -4817.6%
Revenue $2.1M; Operating income −17,2% YoY.
- ▍Revenue $2.1M
- ▍Operating income −17,2% YoY
- ▍Net income −18,9% YoY
- ▍Free cash flow −18,0% YoY
- ▍Net margin -5360.7%
Revenue $2.7M; Operating income +184,4% YoY.
- ▍Revenue $2.7M
- ▍Operating income +184,4% YoY
- ▍Net income +205,0% YoY
- ▍Free cash flow +206,2% YoY
- ▍Net margin 2225.1%
Revenue $17.4M; Operating income -$101.5M.
- ▍Revenue $17.4M
- ▍Operating income -$101.5M
- ▍Net margin -569.1%
Operating income -$98.6M.
- ▍Operating income -$98.6M
Operating income -$98.4M.
- ▍Operating income -$98.4M
Operating income -$56.1M.
- ▍Operating income -$56.1M
Revenue $24.1M; Operating income +11,6% YoY.
- ▍Revenue $24.1M
- ▍Operating income +11,6% YoY
- ▍Net income +17,3% YoY
- ▍Free cash flow +17,9% YoY
- ▍Net margin -1011.7%
Operating income −90,1% YoY; Net income −89,8% YoY.
- ▍Operating income −90,1% YoY
- ▍Net income −89,8% YoY
- ▍Free cash flow −85,1% YoY
Valuation TTM
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -2,86 |
| Revenue | —no estimate | —no estimate | 6,9M USD |
| Operating income | —no estimate | —no estimate | -385,8M USD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Derivative transactions
- Chief Legal Officer · Stock Option (Right to Buy) → Common StockDisposed 5 000 @ $5,06exercise · 2026-07-06
- Director · Stock Option (Right to Buy) → Common StockAcquired 15 528 @ $28,14grant · 2026-06-30
- Director · Stock Option (Right to Buy) → Common StockAcquired 15 528 @ $28,14grant · 2026-06-30
- Director · Stock Option (Right to Buy) → Common StockAcquired 15 528 @ $28,14grant · 2026-06-30
- Director · Stock Option (Right to Buy) → Common StockAcquired 15 528 @ $28,14grant · 2026-06-30
- Director · Stock Option (Right to Buy) → Common StockAcquired 15 528 @ $28,14grant · 2026-06-30
- Chief Medical Officer · Stock Option (Right to Buy) → Common StockDisposed 15 535 @ $5,06exercise · 2026-05-22
- Chief Medical Officer · Stock Option (Right to Buy) → Common StockDisposed 11 317 @ $8,84exercise · 2026-05-22
- Chief Development Officer · Stock Option (Right to Buy) → Common StockAcquired 190 225 @ $26,31grant · 2026-01-26
- Chief Business & Strategy Ofcr · Stock Option (Right to Buy) → Common StockAcquired 190 875 @ $26,31grant · 2026-01-26
- Chief Legal Officer · Stock Option (Right to Buy) → Common StockAcquired 186 200 @ $26,31grant · 2026-01-26
- Director, President, CEO and Chairman · Stock Option (Right to Buy) → Common StockAcquired 745 875 @ $26,31grant · 2026-01-26
- Chief Financial Officer · Stock Option (Right to Buy) → Common StockAcquired 202 225 @ $26,31grant · 2026-01-26
- Chief Scientific Officer · Stock Option (Right to Buy) → Common StockAcquired 216 675 @ $26,31grant · 2026-01-26
- Chief Medical Officer · Stock Option (Right to Buy) → Common StockAcquired 221 450 @ $26,31grant · 2026-01-26
Actions
Ask Handelsavisen
- Reference data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Cash Conversion Ratiooperating_cash_flow / net_income
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Ev To Revenueenterprise_value / revenue
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Market Capmarket_price * shares_outstanding_diluted
- Alumis Inc. Market data — financials · 2026-08-03
- reconciler_enqueue (reconciler) on ALMS.O · 2026-08-03
- Alumis Inc Market data — analyst estimates · 2026-08-03
- Alumis Inc Market data — ESG · 2026-08-03
- ALMS.O HA canonical relationships · 2026-08-03
Ownership & reference
Top holders
- Institutional Investor · as of 2026-03-310,02 %$46M
- Investment Managers · as of 2026-03-310,01 %$23M
- Investment Managers · as of 2026-03-310,01 %$67M
- Investment Managers · as of 2026-03-310,01 %$0M
- Funds · as of 2026-03-310,01 %$33M
- Investment Managers · as of 2026-03-310,00 %$42M
- Investment Managers · as of 2026-03-310,00 %$14M
- Investment Managers · as of 2026-03-310,00 %$16M
- Investment Managers · as of 2026-03-310,00 %$12M
- Investment Managers · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$40M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$2M
- Institutional Investor · as of 2026-03-310,00 %$21M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$5M
- Institutional Investor · as of 2026-03-310,00 %$5M
- Investment Managers · as of 2025-12-310,00 %$40M
- Brokerage Firms · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$5M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2024-12-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Insider activity
- Chief Legal Officer · Common StockSold 5 000 @ $28,00$140K · 2026-07-06
- Chief Legal Officer · Common StockOther 5 000 @ $5,06$25K · 2026-07-06
- Director · Common StockOther 3 553 · 2026-06-30
- Director · Common StockOther 3 553 · 2026-06-30
- Director · Common StockOther 3 553 · 2026-06-30
- Director · Common StockOther 3 553 · 2026-06-30
- Director · Common StockOther 3 553 · 2026-06-30
- Chief Medical Officer · Common StockOther 11 317 @ $8,84$100K · 2026-05-22
- Chief Medical Officer · Common StockOther 15 535 @ $5,06$79K · 2026-05-22
- Director, 10% owner · Common StockOther 680 486 · 2026-04-01
- Director, 10% owner · Common StockOther 1 123 337 · 2026-04-01
- Director, 10% owner · Common StockOther 1 176 470 · 2026-04-01
- 10% owner · Common StockOther 680 486 · 2026-04-01
- 10% owner · Common StockOther 1 123 337 · 2026-04-01
- 10% owner · Common StockOther 680 486 · 2026-04-01
- 10% owner · Common StockOther 1 176 470 · 2026-04-01
- 10% owner · Common StockOther 1 123 337 · 2026-04-01
- 10% owner · Common StockOther 1 176 470 · 2026-04-01
- Director · Common StockBought 588 235 @ $17,00$10,0M · 2026-01-09
- 10% owner · Common StockBought 117 647 @ $17,00$2,0M · 2026-01-08
- 10% owner · Common StockBought 117 647 @ $17,00$2,0M · 2026-01-08
- Director, 10% owner · Common StockBought 294 117 @ $17,00$5,0M · 2026-01-08
- Director, 10% owner · Common StockBought 117 647 @ $17,00$2,0M · 2026-01-08
- 10% owner · Common StockBought 294 117 @ $17,00$5,0M · 2026-01-08
- 10% owner · Common StockBought 294 117 @ $17,00$5,0M · 2026-01-08